Pharming Group to participate in June investor conferences

Rhea-AI Summary

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announced its participation in three key investor conferences in June 2024. CEO Sijmen de Vries will present at the Jefferies Healthcare Conference in New York on June 5. CMO Anurag Relan will join a panel at the Oppenheimer Novel Targets in Immunology Summit on June 24. Additionally, Pharming will attend the Oppenheimer 2024 Montauk Life Sciences Summit from June 26-28. These events aim to provide investors with insights into the company's progress and future plans. Live webcasts and replays will be available on Pharming's website.

Positive

• Pharming will gain exposure through high-profile investor conferences.
• CEO and CMO participation indicates active leadership engagement.
• Live webcasts and replays increase accessibility for global investors.

Negative

• No concrete financial or clinical data updates provided.
• Potentially high travel and participation costs with unclear ROI.
• Focus on presentations without mention of new strategic initiatives or product launches.

Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June:

• Jefferies Healthcare Conference, New York, USA, June 5-6, 2024
  Sijmen de Vries, Chief Executive Officer, will present on Wednesday, June 5 at 10:30EDT/16:30CEST. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.
  

• Oppenheimer Novel Targets in Immunology Summit, New York, USA, June 24, 2024
  Anurag Relan, Chief Medical Officer, will participate in the panel “Taking the Inflammation out of I&I - Novel Approaches for Inflammatory Disorders” on Monday, June 24 at 13:30EDT/19:30CEST.
  

• Oppenheimer 2024 Montauk Life Sciences Summit, Montauk, NY, USA, June 26-28, 2024
  
  

For more information about these conferences, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Jefferies or Oppenheimer representative.

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:

Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000

LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

FAQ

When will Pharming present at the Jefferies Healthcare Conference?

Pharming's CEO, Sijmen de Vries, will present on June 5, 2024, at 10:30 EDT/16:30 CEST.

What is the focus of Anurag Relan's panel at the Oppenheimer Immunology Summit?

Anurag Relan will discuss novel approaches for inflammatory disorders on June 24, 2024, at 13:30 EDT/19:30 CEST.

How can investors access Pharming's presentations?

Live webcasts and replays will be available in the 'Upcoming Events' and 'News' sections of Pharming's website.

Which conferences will Pharming attend in June 2024?

Pharming will attend the Jefferies Healthcare Conference, Oppenheimer Immunology Summit, and Oppenheimer Montauk Life Sciences Summit.